- Home
- PHAR vs TXO Comparison
PHAR vs TXO Comparison
Compare PHAR & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- TXO
- Stock Information
- Founded
- PHAR 1988
- TXO 2012
- Country
- PHAR Netherlands
- TXO United States
- Employees
- PHAR N/A
- TXO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- PHAR Health Care
- TXO Energy
- Exchange
- PHAR Nasdaq
- TXO Nasdaq
- Market Cap
- PHAR 951.7M
- TXO 788.9M
- IPO Year
- PHAR N/A
- TXO 2023
- Fundamental
- Price
- PHAR $13.86
- TXO $14.05
- Analyst Decision
- PHAR Strong Buy
- TXO Strong Buy
- Analyst Count
- PHAR 3
- TXO 2
- Target Price
- PHAR $30.00
- TXO $21.50
- AVG Volume (30 Days)
- PHAR 13.2K
- TXO 142.9K
- Earning Date
- PHAR 10-23-2025
- TXO 11-04-2025
- Dividend Yield
- PHAR N/A
- TXO 17.15%
- EPS Growth
- PHAR N/A
- TXO N/A
- EPS
- PHAR N/A
- TXO 0.30
- Revenue
- PHAR $339,836,000.00
- TXO $332,267,000.00
- Revenue This Year
- PHAR $16.63
- TXO $31.08
- Revenue Next Year
- PHAR $6.77
- TXO $11.32
- P/E Ratio
- PHAR N/A
- TXO $47.27
- Revenue Growth
- PHAR 22.44
- TXO 15.94
- 52 Week Low
- PHAR $7.31
- TXO $13.28
- 52 Week High
- PHAR $17.08
- TXO $20.70
- Technical
- Relative Strength Index (RSI)
- PHAR 51.52
- TXO 50.03
- Support Level
- PHAR $13.63
- TXO $13.42
- Resistance Level
- PHAR $15.27
- TXO $13.88
- Average True Range (ATR)
- PHAR 0.98
- TXO 0.29
- MACD
- PHAR -0.17
- TXO 0.08
- Stochastic Oscillator
- PHAR 16.68
- TXO 83.78
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.